High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The university of Chicago experience
- 29 February 1996
- Vol. 47 (2) , 194-197
- https://doi.org/10.1016/s0090-4295(99)80414-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationCancer, 1994
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.Journal of Clinical Oncology, 1992
- A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.Journal of Clinical Oncology, 1992
- Interleukin-2 toxicity.Journal of Clinical Oncology, 1991
- Association of interleukin-2 therapy with staphylococcal bacteremiaCancer, 1991
- Pathologic findings associated with interleukin-2—Based immunotherapy for cancer: A postmortem study of 19 patientsHuman Pathology, 1990
- Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.Journal of Clinical Oncology, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987